AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s ...

Briefing documents were disclosed relating to the meeting of the U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC), which will convene July 17 on the matter of London-based GSK plc’s Blenrep ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Xospata (gilteritinib) as a treatment for adult patients with relapsed or refractory FLT3-positive ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

A webcast and a conference call for analysts, investors and media representatives will be held on Friday, 18 July 2025 at 13.30 EEST. A link to the live webcast is available on Orion's website at ...

JULY 2025 at 12:00 EEST Orion Group Half-Year Financial Report January-June 2025 April-June 2025 Highlights Net sales totalled EUR 416.5 (April-June ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Ofev (nintedanib) for the treatment of adults with interstitial lung disease caused by systemic sclerosis ...

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.